Presseportal.ch - Daiichi Sankyo

European Results From Global ETNA-AF Registry Show Low Bleeding and Low Cardiovascular Event Rates in Elderly NVAF Patients on LIXIANA® (edoxaban)

info@newsaktuell.ch (presseportal.ch) — Sat, 12 Oct 2019 10:45:35 +0200

Daiichi Sankyo [Newsroom]
- One-year outcomes of real-world edoxaban-treated European patients from the Global ETNA-AF registry showed low rates of potentially life-threatening bleeding and low CV events in elderly NVAF patients1 - The Global ETNA-AF programme is currently ... Lesen Sie hier weiter...

Daiichi Sankyo Announces the Presentation of New Data on LIXIANA® (edoxaban) to be Presented at ESC Congress 2019

info@newsaktuell.ch (presseportal.ch) — Thu, 22 Aug 2019 09:00:40 +0200

Daiichi Sankyo [Newsroom]
- Data presentations from ENTRUST-AF PCI and ETNA-AF add to the growing body of scientific evidence from the Edoxaban Clinical Research Programme - First-time presentation of ENTRUST-AF PCI clincial results assessing edoxaban in atrial fibrillation ... Lesen Sie hier weiter...

Bempedoic Acid CLEAR Serenity Study Results Published in the JAHA Demonstrated Significant LDL-Cholesterol Lowering and Reduced hsCRP in Statin Intolerant Patients

info@newsaktuell.ch (presseportal.ch) — Tue, 02 Apr 2019 13:44:57 +0200

Daiichi Sankyo [Newsroom]
- Bempedoic acid is an oral, once-daily ATP citrate lyase (ACL) inhibitor that reduces cholesterol and fatty acid synthesis in the liver - Bempedoic acid significantly reduced LDL-Cholesterol (LDL-C) vs placebo at week 12 (primary endpoint, ... Lesen Sie hier weiter...

Daiichi Sankyo Initiates Hokusai-VTE Cancer Study to Evaluate the Role of Edoxaban in Patients with Venous Thromboembolism Associated with Cancer

info@newsaktuell.ch (presseportal.ch) — Thu, 18 Jun 2015 14:02:22 +0200

Daiichi Sankyo [Newsroom]
Tokyo (ots/PRNewswire) - Daiichi Sankyo announces the initiation of Hokusai-VTE Cancer, a multinational study investigating edoxaban in venous thromboembolism (VTE) associated with cancer Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) ... Lesen Sie hier weiter...

European Survey Highlights the Risk to Patients Caused by Inconsistency in Hypertension Management

info@newsaktuell.ch (presseportal.ch) — Fri, 08 Jul 2011 08:02:45 +0200

Daiichi Sankyo [Newsroom]
Munich (ots/PRNewswire) - For distribution to the consumer and medical media across Europe (excluding the UK) - Findings From the Supporting Hypertension Awareness and Research Europe-wide (SHARE) Survey Suggest the Need to Implement a Consistent ... Lesen Sie hier weiter...

Global Phase III Trial With Selective c-MET Inhibitor Tivantinib (ARQ 197) Starts Enrolling Patients in Europe

info@newsaktuell.ch (presseportal.ch) — Mon, 18 Apr 2011 08:03:15 +0200

Daiichi Sankyo [Newsroom]
Munich (ots/PRNewswire) - Daiichi Sankyo announced today that it has begun enrolling patients in Europe into a large, multinational phase III trial of tivantinib (ARQ 197). Tivantinib is an investigational small molecule inhibitor of the c-MET ... Lesen Sie hier weiter...

Daiichi Sankyo and ArQule Enroll First Non-Small Cell Lung Cancer Patient Into Global Phase III Trial for ARQ 197

info@newsaktuell.ch (presseportal.ch) — Wed, 12 Jan 2011 16:03:55 +0100

Daiichi Sankyo [Newsroom]
Tokyo and Woburn, Massachusetts (ots/PRNewswire) - Daiichi Sankyo Company, Limited (TSE 4568) and ArQule, Inc. today announced that the first patient has been enrolled in the phase III trial of ARQ 197, an investigational selective inhibitor of ... Lesen Sie hier weiter...

Daiichi Sankyo Announces First European Approval for Sevikar HCT(R), a New Three-in-one Combination Product for the Treatment of High Blood Pressure*

info@newsaktuell.ch (presseportal.ch) — Mon, 20 Dec 2010 10:04:50 +0100

Daiichi Sankyo [Newsroom]
Munich (ots/PRNewswire) - Daiichi Sankyo Europe announced today that Sevikar HCT(R) is now approved in Germany, the first market to launch this new once-daily three-in-one combination product for the treatment of high blood pressure (BP). This ... Lesen Sie hier weiter...

ArQule and Daiichi Sankyo Expand Drug Discovery Collaboration in Oncology

info@newsaktuell.ch (presseportal.ch) — Tue, 12 Oct 2010 12:06:35 +0200

Daiichi Sankyo [Newsroom]
Woburn, Massachusetts (ots/PRNewswire) - ArQule, Inc. and Daiichi Sankyo Co., Ltd. (TSE 4568) today announced the expansion of their research, development and license agreement for the discovery of novel kinase inhibitors in the field of ... Lesen Sie hier weiter...

Patients with Hypertension at Risk Due to Physician Inertia

info@newsaktuell.ch (presseportal.ch) — Mon, 21 Jun 2010 15:31:25 +0200

Daiichi Sankyo [Newsroom]
Oslo, June 21, 2010 (ots/PRNewswire) - Data announced for the first time at ESH suggest that patients with hypertension are at increased cardiovascular risk due to clinician inertia, because physicians are failing to treat targets set by accepted ... Lesen Sie hier weiter...

Daiichi Sankyo Submits First New Drug Application for Oral Factor Xa Inhibitor, Edoxaban

info@newsaktuell.ch (presseportal.ch) — Tue, 06 Apr 2010 12:50:42 +0200

Daiichi Sankyo [Newsroom]
Tokyo, April 6, 2010 (ots/PRNewswire) - Daiichi Sankyo Company, Limited announced today that it has submitted a New Drug Application to the Ministry of Health, Labor and Welfare in Japan seeking approval of the anticoagulant, edoxaban, for the ... Lesen Sie hier weiter...

HOKUSAI VTE - Largest Single Phase III Trial for the Treatment and Prevention of Recurrent VTE Started in Europe

info@newsaktuell.ch (presseportal.ch) — Fri, 26 Feb 2010 11:01:55 +0100

Daiichi Sankyo [Newsroom]
Nuremberg, Germany, February 26, 2010 (ots/PRNewswire) - Edoxaban, a direct oral factor Xa inhibitor, is now being investigated in a second large-scale pivotal phase III trial, HOKUSAI (pronounced hoek-sigh) VTE. This phase III trial is ... Lesen Sie hier weiter...